


Targeting PD-L1 With Chimeric Antigen Receptor Modified NK Cells Induces Tumor Control and Reduction of PD-L1 High Immune Populations

Engineered killer immune cells target tumours and their immunosuppressive allies

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
